Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
Authors:
- 1 June 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (6) , 824-826
Abstract
This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer.Keywords
This publication has 6 references indexed in Scilit:
- Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFRJournal of Clinical Oncology, 2022
- A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinomaCancer Research, Statistics, and Treatment, 2022
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyJournal of Clinical Oncology, 2020
- Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung CancerJournal of Clinical Oncology, 2020
- Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementCancer Research, Statistics, and Treatment, 2019
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaESMO Open, 2017